Caplin Point Q1 FY27 Results: Net Profit Up 18.8% YoY; EBITDA Rises 23%
Caplin Point Laboratories posted strong Q1 FY27 results with net profit up 18.8% YoY to ₹179.09 crore and total revenue rising 20.7% to ₹643.91 crore. EBITDA grew 23% to ₹247 crore with margin expanding to 38.4%, as confirmed per company statement, while US market revenue surged 26% to ₹137 crore. The company holds total liquid assets of ₹2,875 crore and declared a final dividend of ₹4 per share.
*this image is generated using AI for illustrative purposes only.
Caplin Point Laboratories delivered strong financial performance for Q1 FY27, reporting a consolidated net profit of ₹179.09 crore, an 18.8% increase from ₹150.76 crore in Q1 FY26. The company's total revenue climbed 20.7% year-on-year to ₹643.91 crore, supported by accelerated contributions from its US operations and steady expansion in Latin America. This growth trajectory underscores the effectiveness of its dual-market strategy, balancing high-margin regulated markets with volume-driven emerging economies.
The Board of Directors, meeting on August 12, 2026, approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Statutory Auditors, Brahmayya & Co., who issued a limited review report pursuant to Standard on Review Engagements (SRE) 2410. The Board also recommended a final dividend of ₹4 per equity share (200%) for the financial year ended March 31, 2026, subject to shareholder approval at the forthcoming Annual General Meeting (AGM).
Financial Performance Highlights
The company's operational efficiency improved alongside top-line growth, as confirmed per the company statement, with EBITDA rising 23.0% year-on-year to ₹247.0 crore and EBITDA margin expanding to 38.4% from 37.7%. Profit before tax increased by 22.1% to ₹225.23 crore. Basic earnings per share (EPS) grew 15.8% to ₹23.27 from ₹20.10 in the corresponding quarter of the previous year.
| Metric: | Q1 FY27 (₹ Cr) | Q1 FY26 (₹ Cr) | YoY Change (%) |
|---|---|---|---|
| Revenue from Operations | 610.36 | 510.22 | 19.6 |
| Total Revenue | 643.91 | 533.36 | 20.7 |
| US Market Revenue | 137.00 | — | +26.0 |
| EBITDA | 247.0 | 200.9 | 23.0 |
| EBITDA Margin (%) | 38.4 | 37.7 | — |
| Profit Before Tax | 225.23 | 184.43 | 22.1 |
| Net Profit After Tax | 179.09 | 150.76 | 18.8 |
| Basic EPS (₹) | 23.27 | 20.10 | 15.8 |
Gross margin stood at 59.8% in Q1 FY27, slightly down from 61.7% in Q1 FY26. The company maintained a robust balance sheet, with free cash reserves at ₹1,502 crore and total liquid assets reaching ₹2,875 crore as of June 30, 2026.
US Operations and Strategic Developments
The US market emerged as a key growth driver, with total revenue from the segment reaching ₹137 crores in Q1 FY27, representing a 26% increase year-on-year. Caplin Point Steriles Limited (CSL), the subsidiary responsible for US operations, continues to drive this momentum with 60 approved ANDAs and a pipeline of over 40 products under filing or advanced development. CSL has launched 38 products in the US so far, with plans to introduce 12 more in FY27. The company also secured emergency tenders worth $7 million across Central America and $12 million in Chile, reinforcing its presence in Latin America.
In leadership developments, the Board approved the re-appointment of Dr. Sridhar Ganesan as Managing Director for two years, effective August 25, 2026. Additionally, Mr. D. Muralidharan was appointed as Whole-Time Director, effective August 12, 2026, continuing his role as Chief Financial Officer. Both appointments require shareholder approval at the AGM scheduled for September 25, 2026.
What the Numbers Show
The divergence between gross margin contraction (59.8% vs 61.7%) and EBITDA margin expansion (38.4% vs 37.7%) suggests that while input costs or product mix may have pressured initial margins, operational leverage and cost controls at the operating level successfully protected profitability. This indicates disciplined execution in managing overheads despite aggressive capacity expansion initiatives, including new facilities in Puducherry and Chennai aimed at doubling existing capacities by Q1 FY28.
Historical Stock Returns for Caplin Point Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -5.65% | -3.53% | -5.16% | +42.04% | +17.71% | +195.37% |
How will the upcoming capacity expansion in Puducherry and Chennai impact Caplin Point's gross margins once fully operational by Q1 FY28?
What are the potential regulatory risks associated with the 40+ products currently in the US ANDA pipeline, and how might approval delays affect FY27 revenue projections?
Given the recent leadership appointments, how might the strategic focus shift under the new Whole-Time Director and re-appointed Managing Director?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
